Rocket Pharmaceuticals, Inc. (RCKT) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $1.09M; Additional Paid in CapitalUSD $1.73B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-106.00K; Retained Earnings (Accumulated Deficit)USD $-1.37B.
- 2026-03-31: Common Stock, Value, IssuedUSD $1.09M; Additional Paid in CapitalUSD $1.73B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-112.00K; Retained Earnings (Accumulated Deficit)USD $-1.49B.
- 2025-12-31: Common Stock, Value, IssuedUSD $1.08M; Additional Paid in CapitalUSD $1.72B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-31.00K; Retained Earnings (Accumulated Deficit)USD $-1.44B.
- 2025-09-30: Common Stock, Value, IssuedUSD $1.08M; Additional Paid in CapitalUSD $1.71B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-9.00K; Retained Earnings (Accumulated Deficit)USD $-1.40B.
Rocket Pharmaceuticals, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Treasury Stock, Value, Acquired, Cost Method USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Additional Paid in Capital, Common Stock USD | Treasury Stock, Common, Value USD | Treasury Stock, Value USD | Treasury Stock, Common, Shares shares | Treasury Stock, Value, Acquired, Par Value Method USD | Treasury Stock, Retired, Par Value Method, Amount USD | Treasury Stock, Retired, Cost Method, Amount USD | Treasury Stock, Shares, Retired shares | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | Adjustments to Additional Paid in Capital, Warrant Issued USD | Adjustments to Additional Paid in Capital, Increase in Carrying Amount of Redeemable Preferred Stock USD | Treasury Stock, Shares, Acquired shares | Treasury Stock, Shares shares |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.09M | $1.73B | $-106.00K | $-1.37B | $368.83M | (m) | 3 month · $7.42M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $1.09M | $1.73B | $-112.00K | $-1.49B | $238.04M | (m) | 3 month · $8.49M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $1.08M | $1.72B | $-31.00K | $-1.44B | $277.22M | (m) | 12 month · $37.06M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $1.08M | $1.71B | $-9.00K | $-1.40B | $313.67M | (m) | 3 month · $9.76M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $1.08M | $1.70B | $-107.00K | $-1.35B | $354.21M | (m) | 3 month · $10.86M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $1.07M | $1.69B | $-27.00K | $-1.28B | $412.14M | (m) | 3 month · $10.33M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $1.06M | $1.68B | $66.00K | $-1.22B | $463.23M | (m) | 12 month · $43.92M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $911.00K | $1.49B | $213.00K | $-1.16B | $329.77M | (m) | 3 month · $11.25M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $910.00K | $1.48B | $-218.00K | $-1.09B | $384.63M | (m) | 3 month · $11.33M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $906.00K | $1.46B | $-135.00K | $-1.02B | $441.50M | (m) | 3 month · $10.25M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $903.00K | $1.45B | $319.00K | $-959.37M | $492.57M | (m) | 12 month · $39.41M | (m) | $0.00 | (m) | 0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $901.00K | $1.44B | $-508.00K | $-899.71M | $541.09M | (m) | 3 month · $10.32M | (m) | $0.00 | (m) | 0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $805.00K | $1.24B | $-722.00K | $-837.81M | $402.97M | (m) | 3 month · $10.24M | (m) | $47.00K | (m) | 2.57K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $804.00K | $1.23B | $-90.00K | $-772.11M | $458.88M | (m) | 3 month · $8.91M | (m) | (m) | $47.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 2.57K |
| 2022-12-31 | $791.00K | $1.20B | $-357.00K | $-713.77M | $489.69M | 12 month · $47.00K | 12 month · $31.01M | (m) | $47.00K | $47.00K | 2.57K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 2.57K |
| 2022-09-30 | $678.00K | $1.01B | $-596.00K | $-647.05M | $367.31M | (m) | 3 month · $7.68M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $658.00K | $977.10M | $-765.00K | $-589.30M | $387.70M | (m) | 3 month · $7.37M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $645.00K | $952.50M | $-629.00K | $-534.89M | $417.62M | (m) | 3 month · $6.27M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $645.00K | $946.15M | $-161.00K | $-491.91M | $454.72M | (m) | 12 month · $29.24M | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · $12.78M | (m) | (m) | 0.00 |
| 2021-09-30 | $644.00K | $932.78M | $-97.00K | $-447.67M | $485.66M | (m) | 3 month · $6.99M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · $7.58M | (m) | (m) | (m) |
| 2021-06-30 | $634.00K | $886.43M | $-81.00K | $-397.55M | $489.44M | (m) | 3 month · $7.31M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $619.00K | $842.48M | $-75.00K | $-363.02M | $480.00M | (m) | 3 month · $7.90M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $610.00K | $825.79M | $-42.00K | $-322.84M | $503.52M | 12 month · $72.00K | 12 month · $18.57M | (m) | $0.00 | (m) | 0.00 | (m) | (m) | (m) | (m) | (m) | 12 month · $26.56M | (m) | (m) | (m) |
| 2020-09-30 | $552.00K | $503.22M | $69.00K | $-261.93M | $241.84M | (m) | 3 month · $4.05M | (m) | $76.00K | (m) | 3.02K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $551.00K | $498.59M | $229.00K | $-232.85M | $266.52M | (m) | 3 month · $4.49M | (m) | $0.00 | (m) | 0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $551.00K | $493.81M | $-75.00K | $-207.81M | $286.05M | (m) | 3 month · $3.96M | (m) | $429.00K | (m) | 30.56K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $548.00K | $489.93M | $20.00K | $-183.14M | $307.30M | 12 month · $726.00K | 12 month · $13.37M | (m) | $53.00K | (m) | 4.03K | 12 month · $726.00K | 12 month · $0.00 | 12 month · $0.00 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-12 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $100.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $503.00K | $394.93M | $117.00K | $-163.29M | $231.92M | (m) | 3 month · $2.69M | (m) | $344.00K | (m) | 22.31K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $503.00K | $392.20M | $144.00K | $-144.00M | $248.50M | (m) | 3 month · $4.14M | (m) | $344.00K | (m) | 22.31K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-25 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $300.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $451.00K | $302.04M | $-89.00K | $-125.32M | $177.08M | (m) | 3 month · $3.18M | (m) | $0.00 | (m) | 0.00 | 3 month · $727.00K | 3 month · $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-01-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 1 month · $1.30M | 1 month · 100.00K | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $452.00K | $300.25M | $-127.00K | $-105.87M | $194.04M | 12 month · $668.00K | 12 month · $13.60M | (m) | $668.00K | (m) | 50.00K | 12 month · $668.00K | (m) | (m) | (m) | 12 month · $9.30M | (m) | (m) | (m) | (m) |
| 2018-12-28 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.40M | (m) | (m) | (m) | (m) | (m) | (m) | 100.00K | (m) |
| 2018-09-30 | $398.00K | $221.98M | $-207.00K | $-78.55M | $143.62M | (m) | 3 month · $2.61M 9 month · $10.78M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 9 month · $5.30M | (m) | (m) | (m) | (m) |
| 2018-06-30 | $395.00K | $219.22M | $-79.00K | $-62.47M | $157.08M | (m) | 3 month · $2.79M 6 month · $8.17M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · $5.30M 6 month · $5.30M | (m) | (m) | (m) | (m) |
| 2018-03-31 | $394.00K | $216.44M | $10.00K | $-46.70M | $170.15M | (m) | 3 month · $5.38M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · $5.30M | (m) | (m) | (m) | (m) |
| 2017-12-31 | $68.00K | $5.34M | $0.00 | $-31.36M | $15.52M | (m) | 12 month · $1.32M | $316.09M | $0.00 | (m) | 0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | $272.00K | (m) | $-25.00K | $-263.50M | $51.08M | (m) | (m) | $314.33M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $270.00K | (m) | $-72.00K | $-256.11M | $57.53M | (m) | (m) | $313.44M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $270.00K | (m) | $-72.00K | $-249.55M | $63.26M | (m) | (m) | $312.61M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $67.00K | (m) | $-54.00K | $-238.88M | $8.37M | (m) | 12 month · $274.00K | $312.03M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | $269.00K | (m) | $2.00K | $-225.90M | $85.05M | (m) | (m) | $310.69M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $269.00K | (m) | $17.00K | $-214.78M | $95.44M | (m) | (m) | $309.93M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $264.00K | (m) | (m) | $-206.09M | $99.24M | (m) | (m) | $305.07M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $264.00K | (m) | $-11.00K | $-196.02M | $15.54M | (m) | 12 month · $2.38M | $304.58M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · $-131.00K | (m) | (m) |
| 2015-09-30 | $264.00K | (m) | (m) | $-187.85M | $116.47M | (m) | (m) | $304.06M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | $163.00K | (m) | (m) | $-131.89M | $31.72M | (m) | (m) | $163.45M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | $163.00K | (m) | (m) | $-129.50M | $33.95M | (m) | (m) | $163.29M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $10.00K | (m) | (m) | $-128.04M | $-51.56M | (m) | 12 month · $177.00K | $76.47M | (m) | (m) | (m) | (m) | (m) | 12 month · $176.00K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 9 month · $176.00K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | (m) | (m) | $-38.90M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |